Vertex Pharmaceuticals

What Vertex Pharmaceuticals does

Vertex Pharmaceuticals is a Boston-based, publicly traded (NASDAQ: VRTX) commercial-stage biotechnology company founded in 1989 and listed since 1991. It develops and commercializes small-molecule and gene-editing therapies for serious diseases, with a historical concentration in cystic fibrosis (CF) and an expanding portfolio that now spans sickle cell disease, transfusion-dependent beta thalassemia, acute pain, IgA nephropathy, APOL1-driven kidney disease, and Type 1 diabetes. The company serves rare-disease patients globally through a specialty distribution model, operating in 20+ countries with a workforce of approximately 5,000–6,500 employees.

Vertex's core technology centers on CFTR modulators — small molecules that restore function of the defective cystic fibrosis transmembrane conductance regulator protein — which underpin the Trikafta/Kaftrio franchise and the next-generation Alyftrek. Vertex has expanded into gene editing via Casgevy, a CRISPR-Cas9 ex vivo therapy co-developed with CRISPR Therapeutics for sickle cell disease and transfusion-dependent beta thalassemia, priced at approximately $2.2M per patient and delivered through a network of authorized treatment centers. Additional platforms include a non-opioid pain franchise (JOURNAVX/suzetrigine, approved by FDA in early 2025 as the first new mechanism of action for acute pain in over 20 years), the povetacicept BLA-stage asset (acquired through the $4.9B Alpine Immune Sciences deal, PDUFA November 30, 2026), zimislecel for Type 1 diabetes (acquired via the $320M ViaCyte deal in 2022), and inaxaplin for APOL1-driven kidney disease. Discovery is supported by DNA-encoded library screening, human genetics collaborations, and computational chemistry.

Vertex operates a direct-to-patient specialty pharmacy and authorized treatment center model for high-cost, complex therapies (CF franchise, Casgevy) and a more traditional launch infrastructure for JOURNAVX in acute pain. Revenue is generated principally from product sales of Trikafta/Alyftrek, which still represents the dominant share of total revenue, supplemented by Casgevy ramp, the recent JOURNAVX launch, and ex-US partnerships such as Zai Lab in China. FY2025 revenue was approximately $12B, with net income of approximately $4B (~33% margin), and management has guided 2026 revenue to $12.95–13.1B. The company executed $2.02B in share repurchases during 2025 alongside continued M&A and partnership activity.

Name

Vertex Pharmaceuticals

Legal name

Vertex Pharmaceuticals Incorporated

Website

http://www.vrtx.com

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Vertex Pharmaceuticals is a Boston-based biotech developing small-molecule and gene-editing therapies for serious diseases. It serves rare-disease patients globally through a dominant cystic fibrosis franchise (Trikafta/Alyftrek), the CRISPR-based Casgevy for sickle cell disease, and a growing pipeline spanning pain, kidney, and Type 1 diabetes.

Ownership category

akta.pro rank

Product category

Specialty Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Cystic fibrosis treatments
• CRISPR gene therapy
• Small molecule drugs
• Specialty biopharmaceuticals
• Rare disease medicines

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Cystic Fibrosis Portfolio: Vertex's core revenue driver including Trikafta, Alyftrek, and other CFTR modulators. These are specialty pharmaceuticals sold to patients with cystic fibrosis through specialty pharmacies and direct distribution.
2. Casgevy (Gene Therapy): CRISPR-based gene therapy for sickle cell disease and beta thalassemia, co-commercialized with CRISPR Therapeutics. One-time treatment priced at approximately $2.2 million per patient.
3. Journavx (Pain Treatment): Non-opioid pain medication for moderate-to-severe acute pain. Generated approximately $90 million in first-year sales (2025).
4. Povetacicept (if approved): If approved for IgA nephropathy, would be delivered as subcutaneous auto-injector every four weeks for chronic kidney disease treatment.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Vertex Pharmaceuticals discovers, develops, and commercializes transformative medicines for serious diseases. Its portfolio centers on CFTR modulators for cystic fibrosis (Trikafta, Alyftrek), the CRISPR-Cas9 gene therapy Casgevy for sickle cell disease and transfusion-dependent beta thalassemia (co-developed with CRISPR Therapeutics), and the first oral non-opioid acute pain signal inhibitor JOURNAVX (suzetrigine). A growing pipeline includes povetacicept for IgA nephropathy, inaxaplin for APOL1-mediated kidney disease, and zimislecel, a stem cell-derived islet cell therapy for type 1 diabetes.

Product overview

Vertex Pharmaceuticals is a global biotechnology company focused on discovering, developing, and producing transformative medicines for serious diseases. The company operates a portfolio of approved medicines including Trikafta and Alyftrek for cystic fibrosis (its core franchise covering approximately 95% of CF patients), CASGEVY (the world's first CRISPR-based gene therapy for sickle cell disease and beta thalassemia, co-developed with CRISPR Therapeutics), and JOURNAVX (the first FDA-approved oral non-opioid pain signal inhibitor). Vertex's pipeline includes povetacicept for IgA nephropathy (with accepted BLA), inaxaplin for APOL1-mediated kidney disease, zimislecel for Type 1 diabetes, and additional programs in pain, Duchenne muscular dystrophy, and generalized myasthenia gravis. The company also developed Informed Pain Care, a telehealth platform for acute pain management.

Differentiator

Problem solved

Functional benefit

Products and services

• Trikafta (elexacaftor/tezacaftor/ivacaftor) A triple-combination CFTR modulator therapy for cystic fibrosis that targets the underlying cause of the disease by restoring CFTR protein function. Indicated for patients with at least one F508del mutation, representing the largest CF patient population.
• Alyftrek A next-generation CFTR modulator therapy for cystic fibrosis providing improved efficacy with once-daily dosing, expanding coverage to approximately 95% of CF patients in the United States.
• CASGEVY (exagamglogene autotemcel) The first FDA-approved CRISPR/Cas9-based gene therapy, administered at authorized treatment centers to edit a patient's own hematopoietic stem cells ex vivo to reactivate fetal hemoglobin production for the functional cure of severe sickle cell disease and transfusion-dependent beta thalassemia.
• JOURNAVX (suzetrigine) The first FDA-approved oral non-opioid selective NaV1.8 pain signal inhibitor for moderate-to-severe acute pain, providing pain relief without the addiction risks associated with opioid analgesics. Targets an estimated 80 million acute pain patients in North America and Europe.
• Povetacicept An engineered fusion protein dual inhibitor of BAFF and APRIL cytokines in development for IgA nephropathy and other B-cell mediated diseases, with FDA Breakthrough Therapy Designation. Phase 3 RAINIER trial showed 52% proteinuria reduction versus placebo. Planned delivery as a subcutaneous auto-injector every four weeks.
• Inaxaplin An investigational small molecule inhibitor targeting the APOL1 protein in development for APOL1-mediated kidney disease (AMKD), a progressive genetic kidney disorder.
• Zimislecel (VX-880) An allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy in development for Type 1 diabetes patients with impaired hypoglycemic awareness and severe hypoglycemia, designed to restore endogenous insulin production.
• Informed Pain Care A direct-to-patient telehealth platform developed with ixlayer for acute pain evaluation, connecting patients with licensed clinicians and providing access to non-opioid treatment options including JOURNAVX.

Quantifiable outcome

• 95% of US cystic fibrosis patients now eligible for Vertex CF treatments
• +4 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature6 records

Partnerships

Eleven partnerships are on record, tiered minor and core.

• ixlayerminorStrategic or Co-development Partner · 1 June 2026Collaboration on Informed Pain Care telehealth platform for acute pain evaluation and access to non-opioid treatments including Journavx. Direct-to-patient healthcare expansion.
• Ono PharmaceuticalminorStrategic or Co-development Partner · 1 June 2025Strategic agreement announced in June 2025 for development of novel therapies.
• Orna TherapeuticsminorStrategic or Co-development Partner · 1 January 2025Strategic collaboration to develop next-generation approaches for sickle cell disease and transfusion-dependent beta thalassemia using Orna's technology.
• Zai LabminorStrategic or Co-development Partner · 1 January 2025Strategic agreement to develop and commercialize novel therapies.
• Alpine Immune SciencescoreStrategic or Co-development Partner · 1 April 2024Acquired Alpine Immune Sciences for $4.9 billion to obtain povetacicept, a pipeline-in-a-product asset for IgA nephropathy and other kidney diseases. Povetacicept received FDA Breakthrough Therapy Designation.
• CRISPR TherapeuticscoreStrategic or Co-development Partner · 1 March 2023Long-term partnership for co-development and commercialization of Casgevy (exagamglogene autotemcel), the world's first approved CRISPR-based gene therapy for sickle cell disease and beta thalassemia. Vertex leads commercialization with profits split 60/40 (Vertex 60%, CRISPR Therapeutics 40%).
• Entrada TherapeuticsminorStrategic or Co-development Partner · 1 December 2022Collaboration to discover and develop therapies for serious diseases using Entrada's endosomal escape platform.
• ViaCyteminorStrategic or Co-development Partner · 1 July 2022Acquired ViaCyte for $320 million in cash to accelerate stem cell-derived therapies for type 1 diabetes, including VX-880 (now zimislecel) and device encapsulation technology.
• Mammoth BiosciencesminorStrategic or Co-development Partner · 1 October 2021Collaboration to develop in vivo gene editing therapies using Mammoth's CRISPR systems.
• RibometrixminorStrategic or Co-development Partner · 1 September 2019Strategic collaboration to discover and develop small molecule medicines targeting RNA.
• ModernaminorStrategic or Co-development Partner · 1 July 2016Collaboration on inhaled mRNA therapies for cystic fibrosis (VX-522), though the program was discontinued in 2026 due to unresolved tolerability issues with lung inflammation from lipid nanoparticle delivery.

Scale indicators11 records

Recent moves6 records

Expansion highlights8 records

Direct peers

• BioMarin Pharmaceutical: Rare disease-focused biotechnology company with comparable revenue scale (~$2-3B) and similar strategy of developing transformative medicines for serious genetic conditions, including enzyme replacement therapies.
• CRISPR Therapeutics: Co-developer of Casgevy with Vertex (60/40 profit split). Direct strategic partner on the world's first approved CRISPR-based gene therapy for sickle cell disease and beta thalassemia, making it the most directly comparable peer for that product line.
• Biogen: Biotechnology company focused on neurological and rare diseases with similar specialty pharma commercial model. Comparable in therapeutic area focus and approach to serious disease drug development.
• Regeneron Pharmaceuticals: Innovative biotechnology company of similar size with blockbuster franchises (Eylea, Dupixent) treating serious diseases. Comparable in scale, R&D intensity, and focus on developing transformative medicines for high-unmet-need conditions.
• Alnylam Pharmaceuticals: RNA therapeutics pioneer developing innovative medicines for rare diseases. Highly comparable in platform innovation focus, specialty pharma commercial model, and treatment of serious genetic conditions.
• Moderna: mRNA therapeutics company that partnered with Vertex on VX-522 (CF program, discontinued 2026). Both companies are innovative biotechs pursuing platform-based therapeutic approaches for serious diseases.

Broad incumbents

• Novartis: Global pharmaceutical incumbent with first-approved CAR-T therapy (Kymriah) and gene therapy (Zolgensma). Major competitor in cell and gene therapy space with greater scale and resources.
• Pfizer: Global pharmaceutical leader with significant gene therapy investments and rare disease portfolio. Broad incumbent in serious disease therapeutics with multiple competing programs in non-opioid pain, sickle cell disease, and other Vertex focus areas.
• Bristol-Myers Squibb: Large pharmaceutical incumbent with established cell therapy franchises (Breyanzi, Abecma) and broad oncology/specialty portfolio. Provides competitive context as a larger player in cell and gene therapy.
• Gilead Sciences: Large biopharmaceutical company with cell therapy leadership (Yescarta, Tecartus) and virology expertise. Competes broadly in cell therapy and has significant commercial infrastructure advantages.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/VertexPharma
• YouTubeyoutube.com/@Vertex-Pharmaceuticals
• Facebookfacebook.com/VertexPharmaInc
• LinkedInlinkedin.com/company/vertex-pharmaceuticals
• Instagraminstagram.com/vertexpharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries2 records

Funding overview

Funding rounds8 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A9 records

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vertex Pharmaceuticals